News
Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement ...
Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback